(UroToday.com) As part of the “Game-changing Session 4” plenary session at the European Association of Urology (EAU) Virtual Annual Meeting, Dr. Josefsson presented data from the Scandinavian Prostate Cancer Group (SPCG) trial 14, a prospective, open, multicentre, phase II clinical trial of bicalutamide alone or with the addition of docetaxel in nonmetastatic prostate cancer with a rising PSA.